Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics—Relevance to Glioma
暂无分享,去创建一个
[1] San Bernardino,et al. SURVIVAL ANALYSIS , 2020, Statistical Methods for Biomedical Research.
[2] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[3] F. Q. Ribeiro. The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.
[4] Junia C Costa,et al. Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] I. Kovanlikaya,et al. The Added Prognostic Value of Metabolic Tumor Size on FDG‐PET at First Suspected Recurrence of Glioblastoma Multiforme , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[6] G. Liberman,et al. Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study , 2017, Journal of Neuro-Oncology.
[7] Martin Glas,et al. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma , 2016, Oncotarget.
[8] R. Colen,et al. Radiomics in Brain Tumors: An Emerging Technique for Characterization of Tumor Environment. , 2016, Magnetic resonance imaging clinics of North America.
[9] E. Maher,et al. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Brigitta G. Baumert,et al. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1) , 2016, BMC Cancer.
[11] Martin Sill,et al. Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. , 2016, Radiology.
[12] B. Małkowski,et al. Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] Ginu A. Thomas,et al. Diffusion Weighted Magnetic Resonance Imaging Radiophenotypes and Associated Molecular Pathways in Glioblastoma. , 2016, Neurosurgery.
[14] Hui Zhang,et al. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis , 2016, European Radiology.
[15] F. Mulero,et al. Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas , 2016, PloS one.
[16] H. Aerts,et al. Applications and limitations of radiomics , 2016, Physics in medicine and biology.
[17] H. You,et al. Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination , 2016, Medicine.
[18] K. Peck,et al. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. , 2016, Neuro-oncology.
[19] D. Mankoff,et al. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI , 2016, Clinical Cancer Research.
[20] T. Poeppel,et al. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin , 2016, The Journal of Nuclear Medicine.
[21] L. Deangelis,et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.
[22] Daniel J. Brat,et al. Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment , 2016, Chinese journal of cancer.
[23] E. Shimosegawa,et al. Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas , 2016, American Journal of Neuroradiology.
[24] R. Fimmers,et al. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET , 2015, Clinical Cancer Research.
[25] Keith L. Ligon,et al. Somatic mutations associated with MRI-derived volumetric features in glioblastoma , 2015, Neuroradiology.
[26] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[27] Alexander R. Pico,et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.
[28] N. Delcroix,et al. [18F]-fluoro-l-thymidine PET and advanced MRI for preoperative grading of gliomas , 2015, NeuroImage: Clinical.
[29] L. Recht,et al. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. , 2015, Radiology.
[30] David A Gutman,et al. Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death. , 2015, Radiology.
[31] W. Pope. Genomics of brain tumor imaging. , 2015, Neuroimaging clinics of North America.
[32] Xiaofeng Zhou,et al. Bmi1 Drives Stem-Like Properties and is Associated with Migration, Invasion, and Poor Prognosis in Tongue Squamous Cell Carcinoma , 2015, International journal of biological sciences.
[33] S. Nelson,et al. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. , 2014, Cancer research.
[34] T. Nakada,et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy , 2014, Acta neuropathologica communications.
[35] John O. Prior,et al. Combination of MRI and dynamic FET PET for initial glioma grading , 2014, Nuklearmedizin.
[36] Max Wintermark,et al. Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project , 2014, BMC Medical Genomics.
[37] S. Plevritis,et al. Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. , 2014, Radiology.
[38] M. Kuo,et al. Behind the numbers: Decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations. , 2014, Radiology.
[39] P. Larson,et al. Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.
[40] S. Deng,et al. Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis , 2013, Nuclear medicine communications.
[41] T. Nihashi,et al. Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis , 2013, American Journal of Neuroradiology.
[42] Benjamin M Ellingson,et al. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. , 2013, Neuro-oncology.
[43] T. Cloughesy,et al. Probabilistic Radiographic Atlas of Glioblastoma Phenotypes , 2013, American Journal of Neuroradiology.
[44] V. P. Collins,et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.
[45] Ricardo J. Komotar,et al. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? , 2013, Journal of Neuro-Oncology.
[46] Andre Dekker,et al. Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.
[47] O. Chinot,et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. , 2012, Neuro-oncology.
[48] D. Haas-Kogan,et al. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. , 2012, Neuro-oncology.
[49] George Fountzilas,et al. Volumetric and MGMT parameters in glioblastoma patients: Survival analysis , 2012, BMC Cancer.
[50] M. Chaumeil,et al. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma , 2012, NeuroImage.
[51] D. Haynor,et al. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects , 2012, Journal of magnetic resonance imaging : JMRI.
[52] Ferenc A. Jolesz,et al. Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.
[53] Dinesh Rakheja,et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.
[54] P. Sundgren,et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. , 2011, Academic radiology.
[55] Rakesh Kumar,et al. F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study , 2011, Neuroradiology.
[56] C. James,et al. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging , 2011, Journal of magnetic resonance imaging : JMRI.
[57] K. Kang,et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI , 2010, Clinical Neurology and Neurosurgery.
[58] M. J. van den Bent. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta neuropathologica.
[59] Martin J. Bent,et al. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.
[60] M. Senda,et al. Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[61] R. Gonzalez,et al. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. , 2010, Academic radiology.
[62] Sylvia Drabycz,et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging , 2010, NeuroImage.
[63] H. Lanfermann,et al. DIAGNOSTIC VALUE OF PROTON MAGNETIC RESONANCE SPECTROSCOPY IN THE NONINVASIVE GRADING OF SOLID GLIOMAS: COMPARISON OF MAXIMUM AND MEAN CHOLINE VALUES , 2009, Neurosurgery.
[64] Sylvia Drabycz,et al. Predicting MGMT Methylation Status of Glioblastomas from MRI Texture , 2009, MICCAI.
[65] Wei Chen,et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. , 2009, European journal of radiology.
[66] P. Sundgren,et al. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. , 2009, AJR. American journal of roentgenology.
[67] Shigeaki Higashiyama,et al. Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy , 2008, Journal of Nuclear Medicine.
[68] K. Aldape,et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.
[69] J. Llamas-Elvira,et al. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[70] Chen Wei-an,et al. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET , 2007, Journal of Neuro-Oncology.
[71] Hong Liu,et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury , 2007, Journal of Neuro-Oncology.
[72] Isabelle Salmon,et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: Preliminary results , 2006, Journal of magnetic resonance imaging : JMRI.
[73] B. Gulyás,et al. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas , 2006, Journal of the Neurological Sciences.
[74] Wei Chen,et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[75] B. Nan,et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. , 2005, AJR. American journal of roentgenology.
[76] W. Koch,et al. Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas , 2005, Neurosurgery.
[77] Marvin Bergsneider,et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[78] Hans-Jakob Steiger,et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. , 2005, Journal of neurosurgery.
[79] Isabelle Salmon,et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] Jörg-Christian Tonn,et al. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[81] M. Morino,et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery —In malignant glioma— , 2004, Annals of nuclear medicine.
[82] D. Hwang,et al. Prediction of Pathology and Survival by FDG PET in Gliomas , 2003, Journal of Neuro-Oncology.
[83] J. Edmeads,et al. The Clinician's Perspective , 2001, Headache.
[84] G. Barnett,et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery , 2001, International journal of cancer.
[85] U. Spetzger,et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses , 2001, European Journal of Nuclear Medicine.
[86] N. Kuwata,et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining , 1999, Neurosurgical Review.
[87] B. Drayer,et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.
[88] R. Maciunas,et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.
[89] W D Heiss,et al. FDG‐PET as a Prognostic Indicator in Radiochemotherapy of Glioblastoma , 1993, Journal of computer assisted tomography.
[90] R. Coleman,et al. Serial FDG‐PET Studies in the Prediction of Survival in Patients with Primary Brain Tumors , 1993, Journal of computer assisted tomography.
[91] J. Bruner,et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors , 1993, Annals of neurology.
[92] D. Podoloff,et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. , 1992, Radiographics : a review publication of the Radiological Society of North America, Inc.
[93] P. Gutin,et al. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. , 1988, Journal of neurosurgery.
[94] C. Kufta,et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. , 1987, AJR. American journal of roentgenology.
[95] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[96] J. Brenton,et al. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. , 2017, Clinical radiology.
[97] L. Recht,et al. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. , 2016, Radiology.
[98] G. Barger,et al. Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI , 2015, Journal of Neuro-Oncology.
[99] S. Plevritis,et al. Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. , 2015, Radiology.
[100] G. Tabatabai,et al. In vivo visualization of prostate-specific membrane antigen in glioblastoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[101] Benjamin M. Ellingson,et al. Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.
[102] Quanshi Wang,et al. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. , 2012, Chinese medical journal.
[103] I. Mahé,et al. A Prospective Study , 2009 .
[104] Hayden O. Kepley,et al. Preliminary results , 2007 .
[105] R. DeLaPaz,et al. Multisection 1H Magnetic Resonance Spectroscopic Imaging Assessment of Glioma Response to Chemotherapy , 2005, Journal of Neuro-Oncology.
[106] Koen Van Laere,et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[107] Susan M. Chang,et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. , 2001, Magnetic resonance imaging.